Form 4: RA Capital Management Executes Exchange Agreement with Tyra Biosciences, Inc.

RA Capital Healthcare Fund exchanged 1,000,000 shares of Tyra Biosciences' common stock for pre-funded warrants exercisable for the same number of shares at a nominal price.

Summary

• RA Capital Management, L.P., along with related entities and individuals, filed a Form 4 detailing changes in beneficial ownership of Tyra Biosciences, Inc. securities.
• On October 18, 2024, RA Capital Healthcare Fund, L.P. exchanged 1,000,000 shares of Tyra Biosciences' common stock for a pre-funded warrant.
• The pre-funded warrant is exercisable for up to 1,000,000 shares of common stock at an exercise price of $0.001 per share.
• The Exchange Warrant has no expiration date and is exercisable immediately.
• RA Capital Management, L.P. is the investment manager for the Fund, RA Capital Nexus Fund, L.P., and a separately managed account.
• Peter Kolchinsky and Rajeev Shah, managing members of RA Capital Management GP, LLC, disclaim beneficial ownership except to the extent of their pecuniary interest.
• The Reporting Persons shall not be entitled to exercise the Exchange Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 19.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document describes a standard financial transaction. There are no explicit positive or negative implications, but the continued investment by RA Capital could be viewed as a slightly positive signal.

Positives

• The exchange provides RA Capital with increased flexibility through the use of pre-funded warrants.
• The pre-funded warrant allows RA Capital to maintain its position in Tyra Biosciences while managing ownership thresholds.

Risks

• The exercise of the pre-funded warrant is limited to maintain ownership below 19.99%, which could restrict RA Capital's ability to increase its stake in Tyra Biosciences.
• The disclaimer of beneficial ownership by Kolchinsky and Shah could indicate a complex ownership structure that warrants further investigation.

Future Outlook

The document does not contain explicit forward-looking statements, but the exchange suggests RA Capital's continued interest in Tyra Biosciences.

Industry Context

This filing reflects routine transactions by major shareholders in publicly traded companies. The use of pre-funded warrants is a common strategy for managing ownership percentages and providing companies with immediate capital.

Comparison to Industry Standards

• Similar transactions are common among institutional investors in the biotechnology sector, such as Baker Bros. Advisors and OrbiMed Advisors, who frequently adjust their holdings through various financial instruments.
• The 19.99% ownership limit is a standard provision to avoid triggering certain regulatory thresholds and obligations, mirroring practices seen in other investment agreements.

Stakeholder Impact

• The exchange could have a minor impact on shareholders by slightly altering the ownership structure.
• The transaction provides Tyra Biosciences with immediate capital, potentially benefiting the company's operations and future prospects.

Key Dates